Kornimate/medical-research-clean huggingface dataset:
assessement of the soothing effect of a food supplement on sensitive and reactive skin

Conditions: Healthy Volunteers

Summary: the study is aimed to assess the soothing effect of a food supplement composed of coriander seed oil (cso) in terms of reducing skin redness and skin discomfort (stinging feeling) on sensitive and reactive skin.

a double blind, parallel groups, placebo-controlled study is carried out on 80 female subjects aged between 18 and 65 years old with sensitive and reactive skin. the study foresees 56 days of products intake. evaluations of the parameters under study are performed at baseline, after 14, 28 and 56 days of products consumption.

Eligibility criteria:
inclusion criteria : * good general health * caucasian ethnicity * female sex * phototype i to iv * sensitive and reactive skin (showing positive answer from 3-moderate to 4-strong to stinging test performed with a 10% lactic acid solution) * age between 18 and 65 years old (subject with 18 and 65 years old can be included) * subjects who have not been recently involved in any other similar study (evaluation is performed case by case by the experimenter but at least 1 month must be elapsed between a previous study on food supplement) * willingness to use during all the study period only the products to be tested * willingness not to use similar products that could interfere with the product to be tested * willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.) * subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial * subject aware of the study procedures and having signed an informed consent form * subjects who accept not to expose in intensive way to uv rays during the whole study duration * subjects who have not involved in any sun test (for spf evaluation) or tests that provide skin irradiation since less than two months exclusion criteria: * subject does not meet the inclusion criteria, * pregnant/breastfeeding female or who have planned a pregnancy during the study period * subjects under systemically pharmacological treatment * subjects under locally pharmacological treatment on the skin area monitored during the test * subjects with congenital or acquired immunodeficiency * subjects under treatment with food supplements which could interfere with the functionality of the product under study * subjects which show skin alterations on the monitored area which could interfere with the functionality of the product under study * subjects considered as not adequate to participate to the study by the investigator * subjects with known or suspected sensitization to one or more test formulation ingredients * adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated) * subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function
the effect of varying brightness on palpebral aperture

Conditions: Eyelid Ptoses

Summary: we aim to establish the point at which glare from bright lights begins to engage our eyelids - causing us to "squint". we will be using a video camera with an led ring light around it facing the volunteer and we will record the eyelid position as the light brightness is increased gradually. many studies have looked at the effect glare has on a person through qualitative questionnaires but few have been able to quantify this.

our study will aim to establish the point of orbicularis engagement based on luminous intensity murray et al. created an ocular stress monitor to see if the contracture of the muscles on the eyelid indicative of pain as a light source was increased in luminosity 8 our study will go one step further by using video technology and a portable eeg machine to detect the pulses of lid contracture as luminosity of a ring light i s increased incrementally. an advanced calibrated datalogging led light meter will simultaneously record the level of brightness to establish at which point the spike in eeg occurs. screenshots from the video recording will be taken and accurate mrd1 measurements can be taken at the point of orbicular i s engagement. the scientific justification for this research question is twofold we wish to establish the threshold at which orbicularis engages such that palpebral aperture and mrd measurements are altered. this is relevant to the technique of taking these measurements in the clinical environment and the light intensity at which these measurements are taken. we wish to establish the light intensity which should not be exceeded to take these measurements. as photography becomes increasingly used in oculoplastic s clinics we envisage palpebral aperture and mrd1 measurements being performed digitally rather than manually these measurements are relevant to pre operative and post operative imaging, and surgical planning. furthermore, our results maybe applicable more widely to industry, for example vehicle headlights, bicycle lights, camera flash, workplace lighting. reference: murray i, plainis s, carden d. the ocular stress monitor: a new device for measuring discomfort glare. lighting research technology. 2002;34(3):231 239.

Eligibility criteria:
inclusion criteria: * aged between 18 and 65 years of age * a member of the royal free nhs trust exclusion criteria: * no known ocular pathology * no lid problems/ptosis or previous lid surgery * no contact lenses in for duration of experiment * no pseudophakia * no neurological disease

Keywords: palpebral aperture measurements
efficacy of piroxicam as a perioperative analgesic for patients undergoing fixation of maxillofacial fractures

Conditions: Postoperative Pain

Summary: at eldemerdash hospital at ain shams university in egypt, 72 adult patients (16 to 25 years old) who had mandibular or maxillary fractures were treated with open reduction and internal stabilization. patients were divided into two categories. (31 patients each) using randomly generated data from computer, the piroxicam group received 0.4 mg/kg of intramuscular piroxicam, while the general anesthesia group (ga group) did not receive piroxicam. the overall amount of rescue analgesic dosage and postoperative complications like nausea and vomiting were therefore included in the outcomes measurement.

patients were divided into two groups at random using a computer-generated list: the ga group received no piroxicam and the piroxicam group got a 0.4 mg/kg im piroxicam induction. both groups got iv paracetamol (24 mg/kg slowly administered over 20 minutes). fentanyl 2 micrograms/kg was administered after general anesthesia was induced and venous access was established. a suitable size endotracheal tube was then placed intranasal, and intubation was aided by atracurium (0.5 mg/kg). throughout the operation, 1 mac isoflurane in a mixture of 50% air and oxygen was used to maintain anesthesia in all patients who were mechanically ventilated in pressure-controlled mode with targeted etco2 (30-35 mmhg). an oral pack was also introduced. after the operation general anesthesia was stopped and the endotracheal tube was removed, neostigmine 50 mg/kg and atropine sulfate 15 mg/kg were used to reverse muscle relaxation. patient transportation was made to the post-anesthesia care unit (pacu). postoperative analgesia was evaluated by a blind investigator using 10 cm- visual analogue scale score which had been explained to the patient on the preoperative visit where: 0 = no pain, 10 = worst possible pain) in the pacu then at 3, 6, 12, 24 hours, if the pain score \>3, pethidine 25 mg intravenously and ondansetron 0.1mg/kg was used for cases with nausea or vomiting.

Eligibility criteria:
inclusion criteria: * patients aged from 16-25 years old * asai ii * scheduled for open reduction and internal fixation of mandibular or maxillary fractures exclusion criteria: * a history of convulsion, * gastrodudenal ulcer * hematological disorders * patient suffering from hepatic or renal dysfunction * concomitant use of anticoagulants * refusal of the patients to participate * patients younger than 12 years

Keywords: piroxicam vas fractures
understanding patient experience and preferences for the qt scanner compared to mammography

Conditions: Breast Cancer Screening

Summary: this study aims to characterize patient experience, satisfaction and preference for use of the qt scanner in comparison to mammography by directly engaging women who have experience with both technologies.

the objectives will be addressed by first conducting structured one-on-one interviews with about 20 women (qualitative phase), and then administering a web-based patient survey with quantitative measurements in about 200 women (quantitative phase). the current protocol registration pertains to the first, qualitative phase of the study.

Eligibility criteria:
inclusion criteria: * have used the qt scanner * have used mammography * speak english * willing to provide consent and participate in the survey exclusion criteria: • excluded if all inclusion criteria are not met
metabolic syndrome and fall risk

Conditions: Metabolic Syndrome; Autonomic Neuropathy

Summary: obesity and the metabolic syndrome (mets) are rapidly growing problems. individuals with the mets are at risk for not only future chronic diseases, but they have a higher prevalence of neuropathy, including cardiac autonomic neuropathy, and have a higher incidence of falls. currently there are no effective therapies to prevent or reverse the neuropathy seen in the mets or to reduced the fall risk in this population. this research project will determine if a tailored balance exercise program will have functional benefits and result in a reduced fall risk in the growing population of patients with the mets and neuropathy.

completed 55 participants with evidence of the mets and autonomic neuropathy will be assessed for fall risk with the four square step test (fsst), which is a measure of dynamic standing balance. additional endpoints include the dynamic gait index. measures of height, weight, and waist circumference will be taken and an oral glucose tolerance test as well as lipids and blood pressure will also be measured. autonomic function will be measured using cardiac autonomic testing, quantitative sudomotor axon reflex test and tilt table testing. participants will be randomized into either a standard care group that will receive fall risk education or a targeted balance exercise intervention group. both groups will meet once a week. the intervention group will receive a 12 week balance program with personalized incremental increases in the amount and difficulty of each maneuver.

Eligibility criteria:
inclusion criteria: * mets at the time of screening based on the international diabetes federation definition * no risk factors for other causes of neuropathy * autonomic neuropathy as defined by the toronto diabetic neuropathy expert group 2010/11 consensus criteria * age 45-75 years inclusive at the time of screening * medically stable at the time of enrollment * able to participate in a standing balance exercise program without constant standby monitoring * women of childbearing potential must be using an acceptable method of contraception for the duration of their participation in the study * willing to accept assignment to either training group * willing and able to participate in the assigned intervention program exclusion criteria: * pregnant women, prisoners, institutionalized subjects and other at risk subjects * etiology of neuropathy other than the mets * history of severe medical conditions likely to shorten lifespan or alter ability to participate in the trial * severe autonomic neuropathy that restricts daily function and the ability to participate in study interventions * an inability to understand or cooperate with the procedures of the trial or refusal to sign the informed consent

Keywords: neuropathies metabolic diseases nervous system diseases peripheral nervous system diseases
healthy weight management project for overweight and obesity children

Conditions: Obesity

Summary: childhood obesity is a significant public health concern worldwide. in china, childhood obesity has dramatically increased as the economy has grown quickly over the past decades. nonalcoholic fatty liver disease (nafld) is tightly associated with obesity, in china, the prevalence of nafld in obesity children is 40.0%，the main interventions for nafld are lifestyle interventions. effective strategies to helping students lose weight and alleviate nafld through lifestyle interventions may help promote the physical and mental health of obese students. this study aimed (1)to assess the effectiveness of the intervention compared with the usual practice in treating childhood overweight and obesity; (2) to determine the sustainability of the treatment in preventing overweight and obesity; (3) to help alleviate or reverse nafld in obesity children. children with overweight and obesity in six primary schools in ningbo city, zhejiang province will be seleted and randomly divided into two groups: the treatment group and the usual practice group. the participants of the study were students in the third grade of primary school, and the treatment will last for one academic year. this treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.


Eligibility criteria:
inclusion criteria: * parents agree and support their children's weight loss, and students and parents have informed consent; * students in third grade aged 8 and 10 years old; * students with childhood overweight/obesity defined according to the criteria for chinese children and adolescents. exclusion criteria: * medical history of heart disease, hypertension, diabetes, tuberculosis, asthma, hepatitis or nephritis; * obesity caused by endocrine diseases or side effects of drugs; * abnormal physical development like dwarfism or gigantism; * physical deformity such as severe scoliosis, pectus carinatum, limp, obvious o-leg or x-leg; * inability to participate in school sport activities; * a loss in weight by vomiting or taking drugs during the past 3 months.
neurophysiology-based intervention of foot dysfunction in sportive children

Conditions: Flatfoot, Flexible; Sports Physical Therapy; Child Development

Summary: the goal of the clinical trial study is to test the effect of the individual complex physiotherapy intervention program in the children actively playing soccer with flatfoot or valgus foot. the aims are: 1. see if the medial longitudinal arch will by actively more higher after the intervention 2. see if the type of the foot will change toward more neutral type after the intervention 3. see if the transfer of the centre of body mass through the foot during the gait will directed in more neutral line after the intervention the participants will undergo clinical assessment of short kinesiology assessment visually in underwear and barefoot. then participant will be tested for balance test in narrow stance with open and closed eyes, and single.leg stance with open eyes on the pressure mat. finally, participant will walking in self-selected normal speed through the gait pressure mat. eaxh procedure will be measured twice, before the program start and after the 4 weeks when the program finish. researchers will compare these two measurement for the changes.

the aim of the study was to evaluate the effect of the neurophysiology-based (nb) intervention program in sporting children with foot problems. the nb intervention composed from evidence based and neurophysiology-based methods: 1) janda´s sensorimotor stimulation, 2) dynamic neuromuscular stabilisation concept (dns), 3) toe and foot muscle strengthening, 4) foot support base related exercises, and 5) somatic-sensory facilitation techniques. the proposed nb intervention lasted 4 weeks with each 45minutes long session twice a week. each session was leaded by experienced physiotherapist in clinical practice gym, in one-to-one regime to ensure quality of the exercising, using progressive steps and some additional balance pads and small ball. the research assessments were conducted pre- and post-intervention (t0 and t4) and consisted of personal data and health questionnaires (name, date of the birth, laterality, shoe size, diseases, injuries and surgery), clinical examining (standing posture, core stabilisation function in supine position, foot posture index), laboratory testing (postural stability and normal walking on pressure mat). data were edited, analysed and compared pre- and post-intervention.

Eligibility criteria:
inclusion criteria: * age 9-10 years * playing football at least for one year and train twice a week * fpi above 5 * csi above 45.1% exclusion criteria: * acute pain, injury * injury of musculoskeletal system (past 6 months) * infectious disease * cardiovascular, metabolic, neurologic or orthopaedic diseases * active wearing the orthotic devices or aids or barefoot shoes * previous surgery on the lower limbs or pelvis
evaluate dental plaque benefit of a preventive treatment gel

Conditions: Dental Plaque

Summary: the objective of the study is to evaluate anti-plaque efficacy of a preventive treatment gel in a modified 4-day plaque model.


Eligibility criteria:
inclusion criteria: * provide written informed consent prior to participation and be given a signed copy of the informed consent form; * be 18 years of age or older; * agree not to participate in any other oral/dental product studies during the study; * agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed; * agree to refrain from the use of any non-study oral hygiene products (subjects who are regular flossers will be allowed to floss during acclimation and wash-out periods); * agree to use an oral hygiene product that contains stannous fluoride; * agree to refrain from any form of non-specified oral hygiene during the treatment period, including the use of products such as floss, toothpicks for plaque removal, and chewing gum; * agree to refrain from any oral hygiene, eating and drinking after 11:00 pm the evening before plaque measurements on day 0 and day 4 of the treatment periods; * agree to return for all scheduled visits and follow study procedures; * possess a minimum of 20 natural teeth with scorable facial and lingual surfaces, of which at least 4 are molars; and, * be in good general health, as determined by the investigator/designee based on a review of the health history/update for participation in the study. exclusion criteria:• have a medical condition requiring pre-medication prior to dental procedures; * have taken antibiotics within 2 weeks of the acclimation period or anticipate taking antibiotics at any time during the study; * have a history of allergies or hypersensitivity to dyes or dentifrices that contain stannous fluoride; * have removable or orthodontic appliances which interfere with obtaining 20 gradable teeth; * have previously demonstrated an inability to comply with study visit requirements; * have rampant caries, open or untreated caries, severe gingivitis or advanced periodontitis requiring prompt treatment; or, * present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study.
natural history study - mitochondrial disease

Conditions: MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier

Summary: carriers of the m.3242a\>g mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. the investigators would like to learn more about these disorders and have designed a "natural history study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. the focus of the current work is to evaluate known mutation carriers of the m.3243a\>g (mitochondrial dna) and their maternal relatives (carrier status not a requirement for participation). paternal relatives will serve as controls. this study involves no treatment.

the purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 a\>g mutation. mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (dna) and mitochondrial (mt) dna. mitochondrial dna mutations impair mitochondrial function, and cause cellular energy failure. these mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. the investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. this study does not involve any experimental or approved therapy. the investigators will evaluate the patient's condition with blood/urine tests, neurological exam, mri/mrs, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.

Eligibility criteria:
inclusion criteria: known carrier of a the m.3243 a\>g mitochondrial mutation, ,or maternally related to someone who carries the m.3243a\>g mitochondrial mutation. a family member who is not maternally related to someone who carries the m.3243a\>g mitochondrial mutation exclusion criteria: * younger than 4 years of age * no confirmed m.3243 a\>g mitochondrial dna mutation in the family.

Keywords: melas mitochondrial dna mutation mtdna mutation mitochondrial dna mitochondria m.3243a>g mutation
tissue removal assessment with ultrasound of the sfa and popliteal

Conditions: Peripheral Artery Disease; PAD; Claudication; Peripheral Vascular Disease; PVD

Summary: ivus imaging will be utilized to assess performance of the sponsor's orbital atherectomy system (oas) followed by adjunctive balloon angioplasty (ba) in patients who have symptomatic peripheral artery disease (pad) occurring in the superficial femoral artery (sfa), popliteal (pop), and/or tibioperoneal trunk (tpt).

this study is a prospective, single-arm (non-randomized), post-market study which will enroll up to 25 subjects. intravascular ultrasound (ivus) imaging and angiography will be used to assess procedural outcomes in patients who have symptomatic peripheral artery disease who are treated with the sponsor's oas and adjunctive balloon angioplasty. an independent ivus core lab will be used to provide adjudicated analyses for ivus outcomes. in clinic follow-up visits will be performed at 2 weeks, 6 months and at 12 months.

Eligibility criteria:
inclusion criteria: * subject's age ≥ 18 years * subject is an acceptable candidate for percutaneous intervention using the sponsor's oas in accordance with its labeled indications and instructions for use * target lesion(s) located in a superficial femoral artery (sfa), popliteal (pop) or tibioperoneal trunk (tpt) * tight lesions (\>70% stenosis) * lesions less than 110 mm in length * artery with the vessel \< 6.5 mm in diameter * subject is willing and able to sign an approved informed consent form * subject is willing and able to attend follow-up visits exclusion criteria: * uncontrolled allergy to nitinol, stainless-steel or other stent materials or to contrast agent * unable to take appropriate antiplatelet therapy * subject has no distal run-off * interventional treatment is intended for in-stent restenosis at the peripheral vascular site * subject has history of coagulopathy or hypercoagulable disorder, is undergoing hemodialysis or has impaired renal function (cr \> 2.5 mg/dl) at the time of treatment * female subject who is pregnant or nursing a child * intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the sponsor's oas

Keywords: peripheral artery disease pad claudication peripheral vascular disease pvd orbital atherectomy balloon angioplasty intravascular ultrasound (ivus)